The need for external quality control for drugs-of-abuse urinalysis has long been recognized. Based on experiences in other countries, a proficiency testing program has been introduced recently in Spain. Sterile urine samples containing different concentrations of drugs and metabolites are analyzed by participating laboratories four times a year. Comprehensive educational reports reviewed by an advisory committee are released after each batch analysis. The first year's results verify (a) a beneficial influence of the program in regard to reducing errors when adequate techniques are used, (b) the need for using confirmatory techniques, and (c) the importance of experience and laboratory resources for optimizing results. The educational aspects of the program for the second year are stressing especially the in situ training of analysts and the supply of solutions of drugs and metabolites to be used as reference standards. of laboratories, although this is being considered for the future. The initial focus has been to ascertain the status ofdrug analysis in Spain, to detect its main problems, and to improve the education of the analysts involved.
sis. Each laboratory could choose which groups ofdrugs it would analyze. Only screening or additional confirmatory analyses were considered. In 1987, the laboratories enrolled in the program received fourshipmentsofsix samples each. The samples contained from none to four of the substances included in the menu (Table 1) . Twenty working days were allowed for the analysis of the samples. One month after the return of the results to the Coordinating Center (Institut Municipal d'InvestigaciO Medica, Barcelona), the laboratories received a comprehensive coded report for that shipment (see below). A unique code number had been assigned to each laboratory, known only to the Coordinating Center.
By the end of 1987, the number of laboratories enrolled in theprogram had increased from the initial 13 to 25; 14 more were added the next year.
Five non-Spanish laboratories (see Acknowledgments), acted as reference centers, validating the content of the samples. An advisory committee (see Acknowledgments), experts in the analysis and pharmacology of abused drugs, helped the establishment of the testing criteria and performed the follow-up of the program.
The Participating Laboratories
Of the 25 laboratories participating in 1987, 13 were public clinical centers involved in detoxification programs or methadone maintenance treatments, five were laboratories in public hospitals, three were medical school laboratories, two were laboratories involved in research and forensic analysis, and two were private laboratories.
These laboratories were classified into three groups (Table 2), according to (a) the number of analytes (groups) tested, (b) the techniques used, (c) the number ofworkers performing urinalysis for abused drugs, and (d) the number of samples analyzed per year. In each case, a number of points (partial score) was assigned to each laboratory as described in Table 2 . The partial scores were used to assign the final classification, based on the following algorithm: (A + 2B + C + 2D)/4. This emphasized the importance of techniques used (b) and number of samples analyzed (d). Laboratories with a finalscore between 2 and 2.9 points were included in group 1 (n = 13), theones with 3-3.9 points made up group 2 (n = 9), and thosewith 4-4.9 pointswere included in group 3 (n = 3). Positive results for the added drugs (see groups listed in Table 1 )were confirmedas follows: #{149} Amphetamine and phenylpropanolamine were measured by gas chromatography with nitrogen-phosphorus detection (GC-NPD) and GC-MS (7).
Preparation and Control of the Samples
#{149} Cocaine and benzoylecgonune were extracted with chloroform:isopropanol (9:1, by vol), after alkalinizing the urine (8) . The organic layerwas evaporated and the residuewas trimethylsilylated (9) before analysis by CC-MS.
#{149} Benzodiazepines
were measured by thin-layer chromatography (TLC) (7) and also by CC-MS. The latter was also used fordextropropoxyphene.
Samples were extracted as for cocaine, but the residuewas not triinethylsilylated before CC-MS.
#{149}
Barbiturates were measured by CC-MS after acidifying the urine and extraction with chloroform:isopropanol with a TD analyzer (Abbott Laboratories, North Chicago, IL) and gas chromatography-mass spectrometry (GC-MS).' If no undesired drugs were detected, the urine was ifitered through a 0.45-jtm (pore-size) filter, with use of nitrogen pressure. The drugs or metabolites were then added to the filtered urine. The ifitration instrument, its ifiters, the 5O-mL glass vials to contain the samples, and the rubber stoppers of the vials were sterilized at 120 #{176}C and 101 kPa for20 miii. After that, thesamples were sterilized by ifitration through a ifiter and preffiter (poresizes 0.22 and 0.45 pm, respectively) in a laminar-flux cupboard. The urine ofeach batchwas filtered directly into 50-mL, labeled, sterile, glass vials, which were immediately stoppered and sealed in the sterile cupboard. An aliquot ofthe filtered urine was subsequently tested for sterility.
The prepared samples were storedat 4#{176}C. After preparing the six pools of samples in each shipment 'Nonstandard abbreviations:
FPIA, fluorescence polarization unmunoassay; GC-MS, gas chromatography-mass spectrometry; GC-NPD, gas chromatography with nitrogen-phosphorus detection;
and TLC, thin-layer chromatography.
Amphetamine group

Amphetamine Phenyipropanolamine
Barbiturates group Secobarbital
Phenobarbital Pentobarbital
Benzodia.zepines group Oxazepam Nordiazepam Flunitrazepam
Opiates group
Morphine
Morphine-3-glucuronide Codeine
Other opiates group
Methadone
Meth. metabolite (EDDP)
Dextropropoxyphene Naltrexone
Cocaine and (or) cocaine metabolites group
Cocaine Benzoylecgonine
Cannabinoids group
Cannabinoids #{149} Includedin the sets ofsamplessentoutfor testingduring1987.
bConatjon for morphineplusmorphine-3-glucuronide.
#{176}Concentration for methadone plus metabolites. 
Groups analyzed (A)
1
#{149} Morphine was measured
by CC-MS and TLC (7) . Morphine was also detected by "high-performance" liquid chromatography (HPLC), as was morphine-3-glucuronide (10). Codeine was measured by GC-NPD, GC-MS, TLC (7) , and HPLC (10). Methadone was measured by GC-NPD and CC-MS (7). Naltrexone was detected with GC-MS and HPLC (10).
#{149} Cannabinoids
were measured by GC-MS (9) and TLC, with use of the same extraction procedure in both techniques (9) . For TLC, 0.25-mm-thick silica gel G plates (E. Once the batcheswere prepared and checked,they were assigned randomly generated numbers.
A set of six vials and a results reporting sheet were placed in a plastic box with packing to prevent breakage. was guaranteed with a sealing system similar to that used the HPLC was less important. Some laboratories used mA The errors generated by all the laboratories when particiand commercial TLC methods as screening techniques. pating forthefirst time in the program was 3.6% ofthetotal
The percentage oferrors, especially false-positive results, number of analyses (Figure 1) . After four consecutive batchdecreased when results by the EMIT technique were comes, this percentage dropped to 1.3% for the initial 13 bined with a chromatographic technique (from 1.7% to 0.5% laboratories that completed the whole cycle, for false positives and from 2.0% to 1.5% for false negatives, Grouping the laboratories according to the criteria desee Figure 2 ). The number of errors decreased to 0.3% for scribed in Table 2 demonstrated that the group 3 laboraboth false-negative and false-positive results (last bar in tories (good instrumentation and a large number ofsamples Figure 2 ) if confirmation analysis by commercial TLC was to be routinely processed by a largestafi) had a low number omitted. of false results (Table 4 ).Laboratories in group 1 (quite Complete (100%) success was reachedonly in the analysis small, using only enzyme immunoassay, and analyzing only for amphetamine itself (Table 3) . There was a large number a few analytes from the program menu) had a relatively low of false-negative results in the amphetamine group (n = 12), number of errors and improved theirperformance during most of them related to the presence of phenylpropanolthe program. Of special notewas the large number oferrors amine in the samples. According to the rules of the program, of laboratories in group 2, which had a lot of false-negative the presence of phenylpropanolainine in concentrations
>5
results in all batches despite some improvement in eliminatmg/L should be reported as positive for the amphetamine ing false positives, group. Most of the laboratories using EMIT for screening The majority of participating laboratories used EMIT a Laboratoriesgrouped according to the criteria described in Table 2 ; no. per group as in Table 2 .
bThe batch numbers refer to the number of batches analyzed by each laboratory during 1987 (see Figure 2) . It depends on the date of initial participationof each laboratory in the Program (see Figure 1) . FP: false positive, FN: false negative. These kind of interpretative errors should disappear in the future (see I in the Discussion).
The situation was different for the false positives (n = 9) for cocaine when only benzoylecgonine was present. Some laboratories faced with a positive result in the test for benzoylecgonine by EMIT reported a positive result for cocaine instead of, or in addition to, benzoylecgonine when according to the program instructions only benzoylecgonine should have been reported.
In the opiates group, most of the false-negative results (n = 8) were related to the presence of codeine and morphine-3-glucuronide in the urines, for which reactivities withtheantibody were lessthan forthefreemorphine when immunological techniques were used or when chromatographic techniques were used without a hydrolysis step. Finally, many false-positive results (n = 14) were reported for the cannabinoids group, primarily from a small group of laboratories that used only EMiT 
Discussion
Emphasis during the first year ofimplementationofthe
Proficiency
Testing Program has been especially directed towards educational activities. Some of the laboratories involved had been just recently created, and the personnel involved had limited experience and knowledge of specific techniques.
Therefore, theminimal concentrations fordetectionhave been maintained relatively high and much attentionwas paidto interpreting and reportingofresults.
_______________________________________________________
The misinterpretation
of cross-reactivities is of special concern to us, because some of the laboratories did not use confirmatory techniques. Apparently, some of the laboratories do not pay attention routinely to possible false positives caused by cross-reactions with some medications not consideredto be abused drugs. When these drugs (e.g., codeine, phenylpropanolamine)
were present in the samples, the report by the Coordinating Center included strong comments stressing the importance of confirmatory techniques.
Enzyme immunoassay isthe screeningmethod of choice among laboratories includedinour program.Itscommercial The use of confirmatory techniques other than commercial TLC significantly reduced the number of errors, both false positives and false negatives. However, even those laboratories having a satisfactory confirmatory level should pay special attention to the way they report a result. Only the specific analyte detected (e.g., benzoylecgonine) should be reported, and the statement that "[the specific drug detected] is compatible with the ingestion of the parent drug" (e.g., cocaine) could be added to the report. Every effort to promote correct interpretation and reporting in the drugs-of-abuse field is important, because reports sometimes can be misunderstood by the press and othernonspecialized media.
The improvement in correct results as laboratories participated in the program is highly significant, especially with respect to the decrease in false positives. For instance, the frequency of false-positive results decreased by more than 10-fold for those laboratories that participated in the program for a complete year. Although the advance in decreasing false-negative results is not so evident, the overall improvement of results is encouraging, as has been observed elsewhere (13) . (e) Removal ofsome drugs should be considered: pentobarbital, because ofits low urinaryexcretion; naltrexone, which is used only in a few controlled clinical trials; and unmetabolized cocaine, which ispresentonly after "crack" ingestion (currently uncommon in Spain) orafter intentional addition to the urine.
The detailed analysis of errors made by laboratories in
(/) Minimal drug concentrations added to the urine will be thosethat yielda response higher than that of the "low" calibrator of the most commonly used screening procedure in our laboratories (enzyme immunoassay). The development of the Proficiency Testing Program carried out so farisconsideredencouragingby the parties involved (administration, Coordinating Center, advisory committee, and participating laboratories). The next step seems to be to interact with otherinternational initiatives in this field, ifany.The possibility ofa European Proficiency TestingProgram shouldbe considered.
